From bounce-mc.us11_45194293.586945-statnews3=agentidea.com@mail253.atl171.mcdlv.net  Tue Oct  9 10:17:01 2018
Return-Path: <bounce-mc.us11_45194293.586945-statnews3=agentidea.com@mail253.atl171.mcdlv.net>
X-Original-To: statnews3@agentidea.com
Delivered-To: statnews3@agentidea.com
Received: from mail253.atl171.mcdlv.net (mail253.atl171.mcdlv.net [198.2.138.253])
	by agentidea.com (Postfix) with ESMTP id 2581340D13
	for <statnews3@agentidea.com>; Tue,  9 Oct 2018 10:17:01 +0000 (UTC)
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; s=k1; d=statnews.com;
 h=Subject:From:Reply-To:To:Date:Message-ID:List-ID:List-Unsubscribe:
 Content-Type:MIME-Version; i=damian.garde@statnews.com;
 bh=uGybLuXT56al39ZlAMMeVXXX6APphkA3TgHDsvcdBnc=;
 b=oVKQW4Vz+DA3h6sEuPbIRkyDSfkU9JBb3i0+8m0z9bDHG8RvIE2yJPdKCg/yakTh9rJmnb/I97m4
   Gptx+AXabtwimP6I30AnWtmSUr/St//5aNavgKpHEQY2j2mW2SU/uv3bmFnFyHTyxSeY5S23Utxk
   hHWgbashbJE3Lo7oypo=
Received: from (127.0.0.1) by mail253.atl171.mcdlv.net id hni01q2ddl4s for <statnews3@agentidea.com>; Tue, 9 Oct 2018 10:16:57 +0000 (envelope-from <bounce-mc.us11_45194293.586945-statnews3=agentidea.com@mail253.atl171.mcdlv.net>)
Subject: =?utf-8?Q?IPO=20haves=20and=20have=2Dnots=2C=20prenatal=20CRISPR=2C=20&=20the=20next=20generation=20of=20scientists?=
From: =?utf-8?Q?STAT=3A=20The=20Readout?= <damian.garde@statnews.com>
Reply-To: =?utf-8?Q?STAT=3A=20The=20Readout?= <damian.garde@statnews.com>
To: <statnews3@agentidea.com>
Date: Tue, 9 Oct 2018 10:16:57 +0000
Message-ID: <f8609630ae206654824f897b6.fecc3a10a2.20181009101614.4303964433.5cf422ed@mail253.atl171.mcdlv.net>
X-Mailer: MailChimp Mailer - **CID4303964433fecc3a10a2**
X-Campaign: mailchimpf8609630ae206654824f897b6.4303964433
X-campaignid: mailchimpf8609630ae206654824f897b6.4303964433
X-Report-Abuse: Please report abuse for this campaign here: https://mailchimp.com/contact/abuse/?u=f8609630ae206654824f897b6&id=4303964433&e=fecc3a10a2
X-MC-User: f8609630ae206654824f897b6
Feedback-ID: 45194293:45194293.586945:us11:mc
List-ID: f8609630ae206654824f897b6mc list <f8609630ae206654824f897b6.196217.list-id.mcsv.net>
X-Accounttype: pd
List-Unsubscribe: <https://statnews.us11.list-manage.com/unsubscribe?u=f8609630ae206654824f897b6&id=8cab1d7961&e=fecc3a10a2&c=4303964433>, <mailto:unsubscribe-mc.us11_f8609630ae206654824f897b6.4303964433-fecc3a10a2@mailin.mcsv.net?subject=unsubscribe>
List-Unsubscribe-Post: List-Unsubscribe=One-Click
Content-Type: multipart/alternative; boundary="_----------=_MCPart_427971620"
MIME-Version: 1.0

This is a multi-part message in MIME format

--_----------=_MCPart_427971620
Content-Type: text/plain; charset="utf-8"; format="fixed"
Content-Transfer-Encoding: quoted-printable

 =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C=
 =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C=
 =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C=
 =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C=
 =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C=
 =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C=
 =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C=
 =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=
=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=
=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C=
 =E2=80=8C =E2=80=8C =E2=80=8C =E2=80=8C

Sponsored by


https://www.statnews.com/category/the-regulars/the-readout/?utm_source=3DS=
TAT+Newsletters&utm_campaign=3D4303964433-MR_COPY_03&utm_medium=3Demail&ut=
m_term=3D0_8cab1d7961-4303964433-150319813


** The haves and have-nots of biotech IPOs
------------------------------------------------------------

As biotech=E2=80=99s unprecedentedly open IPO window wraps up its sixth ye=
ar=2C one fact tends to escape attention: Most of these things are bad inv=
estments.

Analysts at Leerink crunched the numbers on the IPO boom and found that wh=
ile the average return of biotech debutantes is positive=2C the best-perfo=
rming 20 percent of companies account for more than 80 percent of investor=
 benefit. Meanwhile=2C a full 60 percent of biotech IPOs since 2013 have s=
erved up negative returns.

That means=2C essentially=2C that the story of the biotech boom is one of=
 a few overachieving students goosing the numbers for a C-minus class. And=
 yet it=E2=80=99s easy to see why investors keep coming back to the trough=
: A big bet on one of the 20-percenters would more than make up for a few=
 miscalculations on also-ran drug developers.


** Meet the Wunderkinds
------------------------------------------------------------

Each year at STAT=2C we set out to look past the household names of scienc=
e and spotlight the next generation of researchers at work on what could b=
e the next big thing in medicine.

Over the past several months=2C we pored through hundreds of nominations f=
rom across North America. We didn=E2=80=99t set an age limit; we were on t=
he hunt for the most impressive doctors and researchers on the cusp of lau=
nching their careers but not yet fully independent. Most were postdocs=2C=
 fellows=2C and biopharma employees working with more senior scientists. A=
ll are blazing new trails as they attempt to answer some of the biggest qu=
estions in science and medicine.

And now we present them to you. Read more (https://www.statnews.com/meet-t=
he-2018-stat-wunderkinds/?utm_source=3DSTAT+Newsletters&utm_campaign=3D430=
3964433-MR_COPY_03&utm_medium=3Demail&utm_term=3D0_8cab1d7961-4303964433-=
150319813) .

Sponsor content by STAT Plus


** In-depth biopharma=2C business=2C and policy analysis at your fingertip=
s
------------------------------------------------------------

Sign up for STAT Plus to receive in-depth analysis of the biotech and phar=
ma industries=2C exclusive one-on-one interviews with industry pioneers=2C=
 and inside intelligence from Capitol Hill. Don=E2=80=99t be the last to k=
now. Subscribe (https://www.statnews.com/subscribe/?utm_source=3DSTAT+News=
letters&utm_campaign=3D4303964433-MR_COPY_03&utm_medium=3Demail&utm_term=
=3D0_8cab1d7961-4303964433-150319813) today to start reading.


** Biotech is just swimming in money right now
------------------------------------------------------------

Last week=2C public market investors poured about $1.3 billion into biotec=
h=2C according to analysts at Piper Jaffray=2C marking the biggest jump in=
 more than a year. Here=E2=80=99s why that matters: The flow of money into=
 the sector is strongly correlated with its performance=2C and the past fe=
w months of investor interest in biotech reverses two years of negative tr=
ends.

In 2016=2C roughly $6.5 billion left the sector=2C and the following year=
 was just about flat. This year has already seen more than $4 billion flow=
 into biotech=2C rivaling the heady years of the industry=E2=80=99s recent=
 boom.

There are a few likely explanations. For one=2C the headwinds that sent bi=
otech tanking in 2015 =E2=80=94 concerns about a drug pricing crackdown an=
d uncertainty about the 2016 presidential election =E2=80=94 have largely=
 been resolved. And for two=2C in the minds of generalist investors=2C the=
 upward trajectory of biotech and health care at large has come to look mo=
re attractive compared with the once reliable but suddenly volatile tech s=
ector.


** A win for prenatal CRISPR
------------------------------------------------------------

In an early-stage study on mice=2C scientists managed to cure an inherited=
 disease by using CRISPR genome editing on fetuses=2C a promising sign tha=
t the rapidly proliferating technology may offer hope for devastating inbo=
rn disorders.

As STAT=E2=80=99s Sharon Begley reports (https://www.statnews.com/2018/10/=
08/crispr-cures-inherited-disorder-in-mice-paving-way-for-genetic-therapy-=
before-birth/?utm_source=3DSTAT+Newsletters&utm_campaign=3D4303964433-MR_C=
OPY_03&utm_medium=3Demail&utm_term=3D0_8cab1d7961-4303964433-=
150319813) =2C researchers at the University of Pennsylvania and the Children=E2=
=80=99s Hospital of Philadelphia managed to cure a disease called heredita=
ry tyrosinemia type 1 in mice by disabling an errant gene=2C an early vict=
ory that could pave the way to curing genetic disorders before birth.

=E2=80=9CA lot more animal work needs to be done before we can even think=
 about applying this clinically=2C=E2=80=9D said Dr. William Peranteau=2C=
 who co-led the study. =E2=80=9CBut I think fetal genome editing may be wh=
ere fetal surgery once was=2C and that one day we=E2=80=99ll use it to tre=
at diseases that cause significant morbidity and mortality.=E2=80=9D

Read more (https://www.statnews.com/2018/10/08/crispr-cures-inherited-diso=
rder-in-mice-paving-way-for-genetic-therapy-before-birth/?utm_source=3DSTA=
T+Newsletters&utm_campaign=3D4303964433-MR_COPY_03&utm_medium=3Demail&utm_=
term=3D0_8cab1d7961-4303964433-150319813) .


** More reads
------------------------------------------------------------
* Questions about funding and purpose loom over a foundation Congress crea=
ted to help the FDA. (STAT (https://www.statnews.com/2018/10/09/reagan-uda=
ll-foundation-struggles/?utm_source=3DSTAT+Newsletters&utm_campaign=3D4303=
964433-MR_COPY_03&utm_medium=3Demail&utm_term=3D0_8cab1d7961-4303964433-=
150319813) )
* GlaxoSmithKline helps immunometabolism startup Sitryx to $30 million rou=
nd. (FierceBiotech (https://www.fiercebiotech.com/biotech/gsk-helps-immuno=
metabolism-startup-sitryx-to-30m-round?utm_source=3DSTAT+Newsletters&utm_c=
ampaign=3D4303964433-MR_COPY_03&utm_medium=3Demail&utm_term=3D0_8cab1d7961=
-4303964433-150319813) )
* Three biotech companies are expected to go public this week. (Business I=
nsider (https://markets.businessinsider.com/news/stocks/this-week-s-biotec=
h-ipos-1027595664?utm_source=3DSTAT+Newsletters&utm_campaign=3D4303964433-=
MR_COPY_03&utm_medium=3Demail&utm_term=3D0_8cab1d7961-4303964433-=
150319813) )

Thanks for reading! Until tomorrow=2C
Megan

=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=
=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D

Tuesday=2C October 9=2C 2018

** STAT (https://www.statnews.com/?utm_source=3DSTAT+Newsletters&utm_campa=
ign=3D4303964433-MR_COPY_03&utm_medium=3Demail&utm_term=3D0_8cab1d7961-430=
3964433-150319813)

** Facebook (https://www.facebook.com/statnews/?utm_source=3DSTAT+Newslett=
ers&utm_campaign=3D4303964433-MR_COPY_03&utm_medium=3Demail&utm_term=3D0_8=
cab1d7961-4303964433-150319813)
** Twitter (https://twitter.com/statnews/?utm_source=3DSTAT+Newsletters&ut=
m_campaign=3D4303964433-MR_COPY_03&utm_medium=3Demail&utm_term=3D0_8cab1d7=
961-4303964433-150319813)
** YouTube (https://www.youtube.com/channel/UC89FjSf9AT1O2qw6vxrrxDQ?utm_s=
ource=3DSTAT+Newsletters&utm_campaign=3D4303964433-MR_COPY_03&utm_medium=
=3Demail&utm_term=3D0_8cab1d7961-4303964433-150319813)
** Instagram (https://www.instagram.com/statnews/?utm_source=3DSTAT+Newsle=
tters&utm_campaign=3D4303964433-MR_COPY_03&utm_medium=3Demail&utm_term=3D0=
_8cab1d7961-4303964433-150319813)
1 Exchange Pl=2C Suite 201=2C Boston=2C MA 02109
_icu.png?id=3DX4417792&campaign=3D%7C4972%7C&data=3D=
statnews3@agentidea.com _itu.png
=C2=A92018=2C All Rights Reserved.
** I no longer wish to receive STAT emails (https://statnews.us11.list-man=
age.com/unsubscribe?u=3Df8609630ae206654824f897b6&id=3D8cab1d7961&e=3D=
fecc3a10a2&c=3D4303964433)

** Update Email Preferences (https://statnews.us11.list-manage.com/profile=
?u=3Df8609630ae206654824f897b6&id=3D8cab1d7961&e=3Dfecc3a10a2)
| ** Contact Us (https://www.statnews.com/contact/?utm_source=3DSTAT+Newsl=
etters&utm_campaign=3D4303964433-MR_COPY_03&utm_medium=3Demail&utm_term=3D=
0_8cab1d7961-4303964433-150319813)
| ** View In Browser (https://mailchi.mp/statnews/tk-586945?e=3Dfecc3a10a2)
5cP.gif?contact_status=3DNewsletter Only
--_----------=_MCPart_427971620
Content-Type: text/html; charset="utf-8"
Content-Transfer-Encoding: quoted-printable

<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www=
=2Ew3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns=3D"http://www.w3.org/1999/xhtml" xmlns:v=3D"urn:schemas-micros=
oft-com:vml" xmlns:o=3D"urn:schemas-microsoft-com:office:office">
  <head>
    <!-- STAT newsletter Template for MailChimp -->
    <!--[if gte mso 15]>
    <xml>
      <o:OfficeDocumentSettings>
        <o:AllowPNG />
        <o:PixelsPerInch>96</o:PixelsPerInch>
      </o:OfficeDocumentSettings>
    </xml>
    <![endif]-->
    <meta charset=3D"UTF-8">
    <meta http-equiv=3D"x-ua-compatible" content=3D"IE=3Dedge">
    <meta name=3D"viewport" content=3D"width=3Ddevice-width=2C initial-sca=
le=3D1">
    <title>IPO haves and have-nots=2C prenatal CRISPR=2C & the next genera=
tion of scientists</title>

  <style type=3D"text/css">
=09=09p{
=09=09=09margin:1em 0;
=09=09=09padding:0;
=09=09}
=09=09table{
=09=09=09border-collapse:collapse;
=09=09}
=09=09h1=2Ch2=2Ch3=2Ch4=2Ch5=2Ch6{
=09=09=09display:block;
=09=09=09margin-top:24px;
=09=09=09margin-bottom:0;
=09=09=09padding:0;
=09=09=09color:#000000;
=09=09=09font-family:Arial=2Csans-serif;
=09=09=09font-style:normal;
=09=09=09font-weight:bold;
=09=09=09line-height:130%;
=09=09=09letter-spacing:normal;
=09=09=09text-align:left;
=09=09}
=09=09h1+p=2Ch2+p=2Ch3+p=2Ch4+p=2Ch5+p=2Ch6+p{
=09=09=09margin-top:4px;
=09=09}
=09=09h1+img=2Ch2+img=2Ch3+img=2Ch4+img=2Ch5+img=2Ch6+img{
=09=09=09margin-top:12px;
=09=09}
=09=09h1+p img:first-child=2Ch2+p img:first-child=2Ch3+p img:first-child=
=2Ch4+p img:first-child=2Ch5+p img:first-child=2Ch6+p img:first-child{
=09=09=09margin-top:12px;
=09=09}
=09=09img=2Ca img{
=09=09=09border:0;
=09=09=09height:auto;
=09=09=09outline:none;
=09=09=09text-decoration:none;
=09=09}
=09=09body=2C#bodyTable=2C#bodyCell{
=09=09=09height:100%;
=09=09=09margin:0;
=09=09=09padding:0;
=09=09=09width:100%;
=09=09}
=09=09#outlook a{
=09=09=09padding:0;
=09=09}
=09=09img{
=09=09=09-ms-interpolation-mode:bicubic;
=09=09=09max-width:550px;
=09=09}
=09=09table{
=09=09=09mso-table-lspace:0;
=09=09=09mso-table-rspace:0;
=09=09}
=09=09.ReadMsgBody{
=09=09=09width:100%;
=09=09}
=09=09.ExternalClass{
=09=09=09width:100%;
=09=09}
=09=09p=2Ca=2Cli=2Ctd=2Cblockquote{
=09=09=09mso-line-height-rule:exactly;
=09=09}
=09=09a[href^=3Dtel]=2Ca[href^=3Dsms]{
=09=09=09color:inherit;
=09=09=09cursor:default;
=09=09=09text-decoration:none;
=09=09}
=09=09p=2Ca=2Cli=2Ctd=2Cbody=2Ctable=2Cblockquote{
=09=09=09-ms-text-size-adjust:100%;
=09=09=09-webkit-text-size-adjust:100%;
=09=09}
=09=09.ExternalClass=2C.ExternalClass p=2C.ExternalClass td=2C.ExternalCla=
ss div=2C.ExternalClass span=2C.ExternalClass font{
=09=09=09line-height:100%;
=09=09}
=09=09a[x-apple-data-detectors]{
=09=09=09color:inherit !important;
=09=09=09text-decoration:none !important;
=09=09=09font-size:inherit !important;
=09=09=09font-family:inherit !important;
=09=09=09font-weight:inherit !important;
=09=09=09line-height:inherit !important;
=09=09}
=09=09#bodyCell{
=09=09=09padding:9px;
=09=09=09padding-top:20px;
=09=09}
=09=09.templateContainer{
=09=09=09max-width:600px !important;
=09=09}
=09=09#footerContent{
=09=09=09padding-top:5px;
=09=09=09padding-bottom:0;
=09=09}
=09=09.templatePreheader=2C.templateHeader=2C#templateIntro=2C.templateBod=
y{
=09=09=09padding-right:25px;
=09=09=09padding-left:25px;
=09=09}
=09=09body=2C#bodyTable{
=09=09=09background-color:#F8F8F8;
=09=09}
=09=09.templateContainer{
=09=09=09border:0;
=09=09}
=09=09h1{
=09=09=09font-size:22px;
=09=09}
=09=09h2{
=09=09=09font-size:18px;
=09=09}
=09=09h3{
=09=09=09font-size:16px;
=09=09}
=09=09h4{
=09=09=09font-size:14px;
=09=09}
=09=09h5{
=09=09=09font-size:12px;
=09=09}
=09=09h6{
=09=09=09font-size:10px;
=09=09}
=09=09.templatePreheader{
=09=09=09background-color:#FFFFFF;
=09=09=09background-image:none;
=09=09=09background-repeat:no-repeat;
=09=09=09background-position:center;
=09=09=09background-size:cover;
=09=09=09border:1px solid #EEEEEE;
=09=09=09border-top:3px solid #DDD;
=09=09=09padding-top:9px;
=09=09=09padding-bottom:9px;
=09=09}
=09=09.templatePreheader=2C.templatePreheader p{
=09=09=09color:#000000;
=09=09=09font-family:Arial=2Csans-serif;
=09=09=09font-size:12px;
=09=09=09font-weight:bold;
=09=09=09line-height:150%;
=09=09=09text-align:center;
=09=09}
=09=09.templatePreheader a=2C.templatePreheader p a{
=09=09=09color:#1FADB6;
=09=09=09text-decoration:none;
=09=09}
=09=09.templatePreheader p img{
=09=09=09vertical-align:middle;
=09=09}
=09=09.templatePreheader.standard p img{
=09=09=09margin-bottom:1px;
=09=09}
=09=09.templatePreheader.generic{
=09=09=09border-top:3px solid #1FADB6;
=09=09=09padding-top:8px;
=09=09=09padding-bottom:8px;
=09=09}
=09=09.templatePreheader.generic .columnContainer.first p{
=09=09=09text-align:left;
=09=09}
=09=09.templatePreheader.generic .columnContainer.last p{
=09=09=09text-align:right;
=09=09=09font-weight:normal;
=09=09=09text-transform:uppercase;
=09=09=09letter-spacing:2px;
=09=09=09font-size:10px;
=09=09=09margin-top:16px;
=09=09}
=09=09.templatePreheader.generic .columnContainer.last p a{
=09=09=09color:#BBBBBB;
=09=09}
=09=09.templateSpacer p{
=09=09=09margin:0;
=09=09=09font-size:10px;
=09=09}
=09=09.templateRule{
=09=09=09border-top:1px solid #EEEEEE;
=09=09}
=09=09.templateHeader{
=09=09=09background-color:#FFFFFF;
=09=09=09background-image:none;
=09=09=09background-repeat:no-repeat;
=09=09=09background-position:center;
=09=09=09background-size:cover;
=09=09=09border-top:3px solid #1FADB6;
=09=09=09border-left:1px solid #EEEEEE;
=09=09=09border-right:1px solid #EEEEEE;
=09=09=09padding-top:18px;
=09=09=09padding-bottom:0;
=09=09}
=09=09.templateHeader=2C.templateHeader p{
=09=09=09color:#000000;
=09=09=09font-family:Arial=2Csans-serif;
=09=09=09font-size:17px;
=09=09=09line-height:150%;
=09=09=09text-align:left;
=09=09}
=09=09.templateHeader a=2C.templateHeader p a{
=09=09=09color:#1FADB6;
=09=09=09text-decoration:none;
=09=09}
=09=09.templateHeader p.caption{
=09=09=09text-align:right;
=09=09=09text-transform:uppercase;
=09=09=09font-family:Arial=2Csans-serif;
=09=09=09font-size:11px;
=09=09=09color:#999999;
=09=09=09margin:4px 0 0;
=09=09=09line-height:130%;
=09=09}
=09=09.templateHeader.generic{
=09=09=09border-top-style:none;
=09=09=09padding:1px;
=09=09=09border-bottom:1px solid #EEEEEE;
=09=09}
=09=09.templateHeader.generic img{
=09=09=09vertical-align:top;
=09=09=09max-width:596px;
=09=09}
=09=09.templateBody.generic{
=09=09=09padding-top:9px;
=09=09}
=09=09#templateIntro{
=09=09=09padding-bottom:28px;
=09=09=09background-color:#FFFFFF;
=09=09=09background-image:none;
=09=09=09background-repeat:no-repeat;
=09=09=09background-position:center;
=09=09=09background-size:cover;
=09=09=09border-left:1px solid #EEEEEE;
=09=09=09border-right:1px solid #EEEEEE;
=09=09}
=09=09#templateIntro p{
=09=09=09background-color:#EFF9FA;
=09=09=09text-align:center;
=09=09=09padding:20px;
=09=09=09font-family:Arial=2Csans-serif;
=09=09=09font-weight:bold;
=09=09=09font-size:13px;
=09=09=09margin:3px 0;
=09=09=09line-height:1.35;
=09=09}
=09=09#templateIntro p a{
=09=09=09color:#1FADB6;
=09=09=09text-decoration:none;
=09=09}
=09=09.templateBody{
=09=09=09background-color:#FFFFFF;
=09=09=09background-image:none;
=09=09=09background-repeat:no-repeat;
=09=09=09background-position:center;
=09=09=09background-size:cover;
=09=09=09border-left:1px solid #EEEEEE;
=09=09=09border-right:1px solid #EEEEEE;
=09=09=09border-bottom:1px solid #EEEEEE;
=09=09=09padding-top:0;
=09=09=09padding-bottom:9px;
=09=09}
=09=09.templateBody=2C.templateBody p{
=09=09=09color:#000000;
=09=09=09font-family:Georgia=2Cserif;
=09=09=09font-size:17px;
=09=09=09line-height:150%;
=09=09=09text-align:left;
=09=09}
=09=09.templateBody a=2C.templateBody p a{
=09=09=09color:#1FADB6;
=09=09=09text-decoration:none;
=09=09}
=09=09.templateBody p.cta{
=09=09=09margin:27px 0 40px !important;
=09=09=09font-family:Arial=2Csans-serif;
=09=09=09text-transform:uppercase;
=09=09=09font-size:14px;
=09=09=09letter-spacing:2px;
=09=09}
=09=09.templateBody p.cta a{
=09=09=09color:#FFFFFF;
=09=09=09background-color:#1FADB6;
=09=09=09padding:10px 30px;
=09=09}
=09=09.templateBody p.author{
=09=09=09color:#666666;
=09=09=09font-size:14px;
=09=09=09margin-top:12px;
=09=09}
=09=09.templateBody p.author span{
=09=09=09text-transform:uppercase;
=09=09}
=09=09.templateBody p.caption{
=09=09=09text-align:right;
=09=09=09text-transform:uppercase;
=09=09=09font-family:Arial=2Csans-serif;
=09=09=09font-size:11px;
=09=09=09color:#999999;
=09=09=09margin:4px 0 0;
=09=09=09line-height:130%;
=09=09}
=09=09.templateBody p.caption+p{
=09=09=09margin-top:9px;
=09=09}
=09=09.templateBody img{
=09=09=09vertical-align:text-top;
=09=09}
=09=09.templateBody ul{
=09=09=09list-style-type:square;
=09=09=09padding-left:17px;
=09=09=09margin-top:4px;
=09=09}
=09=09.templateBody.sponsor p:first-child{
=09=09=09color:#DF4C51;
=09=09=09text-transform:uppercase;
=09=09=09font-family:Arial=2Csans-serif;
=09=09=09font-size:10px;
=09=09=09margin-top:24px;
=09=09=09margin-bottom:0;
=09=09=09letter-spacing:2px;
=09=09}
=09=09.templateBody.sponsor p+h1{
=09=09=09margin-top:4px;
=09=09}
=09=09.templateBody.sponsor a=2C.templateBody.sponsor p a{
=09=09=09color:#DF4C51;
=09=09}
=09=09.templateBody.sponsor.rss p:first-child{
=09=09=09text-decoration:underline;
=09=09}
=09=09.templateBody.sponsor.rss h1{
=09=09=09text-decoration:underline;
=09=09}
=09=09.templateBody.contact{
=09=09=09background-color:#F8F8F8;
=09=09=09background-image:url(https://gallery.mailchimp.com/f8609630ae2066=
54824f897b6/images/82e08a18-2199-4c11-aa0a-6c7b954edcd0.png);
=09=09=09background-repeat:repeat;
=09=09=09background-size:auto;
=09=09=09padding-top:10px;
=09=09=09padding-bottom:10px;
=09=09}
=09=09.templateBody.contact p{
=09=09=09text-align:center;
=09=09=09text-transform:uppercase;
=09=09=09font-family:Arial=2Csans-serif;
=09=09=09font-size:11px;
=09=09=09margin:2em 0;
=09=09=09letter-spacing:2px;
=09=09}
=09=09.templateBody.contact p:last-child{
=09=09=09margin-bottom:3em;
=09=09}
=09=09.templateBody.rss h1{
=09=09=09font-size:24px;
=09=09}
=09=09.templateBody.rss h1 a{
=09=09=09color:#000000;
=09=09=09text-decoration:underline;
=09=09}
=09=09#templateFooter{
=09=09=09background-color:#F8F8F8;
=09=09=09background-image:none;
=09=09=09background-repeat:no-repeat;
=09=09=09background-position:center;
=09=09=09background-size:cover;
=09=09=09border-top:0;
=09=09=09border-bottom:0;
=09=09=09padding-top:0;
=09=09=09padding-bottom:9px;
=09=09=09padding-left:0;
=09=09=09padding-right:0;
=09=09}
=09=09#templateFooter a{
=09=09=09color:#1FADB6;
=09=09=09text-decoration:none;
=09=09}
=09=09#dateBar=2C#dateBar p{
=09=09=09text-align:right;
=09=09=09font-family:Arial=2Csans-serif;
=09=09=09font-size:10px;
=09=09=09color:#999999;
=09=09}
=09=09#logoBar=2C#logoBar p{
=09=09=09font-family:Arial=2Csans-serif;
=09=09=09font-size:17px;
=09=09=09text-align:center;
=09=09}
=09=09#logoBar p{
=09=09=09margin-top:18px;
=09=09=09margin-bottom:9px;
=09=09}
=09=09#socialBar{
=09=09=09background-color:#F8F8F8;
=09=09=09border:0;
=09=09=09padding:0;
=09=09}
=09=09#socialBar=2C#socialBar p{
=09=09=09color:#BBBBBB;
=09=09=09font-family:Arial=2Csans-serif;
=09=09=09font-size:11px;
=09=09=09line-height:150%;
=09=09=09text-align:center;
=09=09=09margin:0;
=09=09}
=09=09#footerContent=2C#footerContent p{
=09=09=09color:#BBBBBB;
=09=09=09font-family:Arial=2Csans-serif;
=09=09=09font-size:11px;
=09=09=09line-height:160%;
=09=09=09text-align:center;
=09=09}
=09=09#footerContent a=2C#footerContent p a{
=09=09=09color:#BBBBBB;
=09=09=09text-decoration:none;
=09=09}
=09=09#utilityBar{
=09=09=09background-color:#F8F8F8;
=09=09=09border:0;
=09=09=09padding-top:0;
=09=09=09padding-bottom:20px;
=09=09}
=09=09#utilityBar=2C#utilityBar p{
=09=09=09color:#BBBBBB;
=09=09=09font-family:Arial=2Csans-serif;
=09=09=09font-size:11px;
=09=09=09line-height:160%;
=09=09=09text-align:center;
=09=09}
=09=09#utilityBar a=2C#utilityBar p a{
=09=09=09color:#1FADB6;
=09=09=09text-decoration:underline;
=09=09}
=09=09#utilityBar a.unsub{
=09=09=09color:#BBBBBB;
=09=09}
=09=09.mcnPreviewText{
=09=09=09display:none !important;
=09=09}
=09@media only screen and (max-width: 480px){
=09=09body=2Ctable=2Ctd=2Cp=2Ca=2Cli=2Cblockquote{
=09=09=09-webkit-text-size-adjust:none !important;
=09=09}

}=09@media only screen and (max-width: 480px){
=09=09body{
=09=09=09width:100% !important;
=09=09=09min-width:100% !important;
=09=09}

}=09@media only screen and (max-width: 480px){
=09=09img{
=09=09=09max-width:100% !important;
=09=09=09height:auto !important;
=09=09}

}=09@media only screen and (max-width: 480px){
=09=09#bodyCell{
=09=09=09padding-left:4px !important;
=09=09=09padding-right:4px !important;
=09=09}

}=09@media only screen and (max-width: 480px){
=09=09.templatePreheader=2C.templateHeader=2C#templateIntro=2C.templateBod=
y{
=09=09=09padding-right:13px !important;
=09=09=09padding-left:13px !important;
=09=09}

}=09@media only screen and (max-width: 480px){
=09=09.templatePreheader.generic .columnContainer.last p{
=09=09=09margin-top:1em !important;
=09=09}

}=09@media only screen and (max-width: 480px){
=09=09.templateHeader.generic{
=09=09=09padding:1px !important;
=09=09}

}=09@media only screen and (max-width: 480px){
=09=09.columnContainer{
=09=09=09max-width:100% !important;
=09=09=09width:100% !important;
=09=09}

}=09@media only screen and (max-width: 480px){
=09=09.columnContainer.last{
=09=09=09display:none !important;
=09=09}

}=09@media only screen and (max-width: 480px){
=09=09.templateBody.rss h1{
=09=09=09font-size:20px !important;
=09=09=09line-height:125% !important;
=09=09}

}</style></head>
  <body style=3D"height: 100%;margin: 0;padding: 0;width: 100%;-ms-text-si=
ze-adjust: 100%;-webkit-text-size-adjust: 100%;background-color: #F8F8F8;"=
>
    <!--
-->
    <center>
      <table align=3D"center" border=3D"0" cellpadding=3D"0" cellspacing=
=3D"0" width=3D"100%" id=3D"bodyTable" style=3D"height: 100%;border-collap=
se: collapse;mso-table-lspace: 0;mso-table-rspace: 0;-ms-text-size-adjust:=
 100%;-webkit-text-size-adjust: 100%;margin: 0;padding: 0;width: 100%;back=
ground-color: #F8F8F8;">
        <tr>
          <td align=3D"center" valign=3D"top" id=3D"bodyCell" style=3D"mso=
-line-height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-ad=
just: 100%;height: 100%;margin: 0;padding: 9px;width: 100%;padding-top: 20=
px;">
            <!-- BEGIN TEMPLATE // -->
            <!--[if gte mso 9]>
            <table align=3D"center" border=3D"0" cellspacing=3D"0" cellpad=
ding=3D"0" width=3D"600" style=3D"width:600px;">
              <tr>
                <td align=3D"center" valign=3D"top" width=3D"600" style=3D=
"width:600px;">
                  <![endif]-->
            <table border=3D"0" cellpadding=3D"0" cellspacing=3D"0" width=
=3D"100%" class=3D"templateContainer" style=3D"border-collapse: collapse;m=
so-table-lspace: 0;mso-table-rspace: 0;-ms-text-size-adjust: 100%;-webkit-=
text-size-adjust: 100%;border: 0;max-width: 600px !important;">
              <!-- BEGIN PREHEADER // -->
              <tr mc:hideable=3D"hideable_1" mchideable=3D"hideable_1">
                <td valign=3D"top" class=3D"templatePreheader standard" st=
yle=3D"background:#FFFFFF none no-repeat center/cover;mso-line-height-rule=
: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;paddin=
g-right: 25px;padding-left: 25px;background-color: #FFFFFF;background-imag=
e: none;background-repeat: no-repeat;background-position: center;backgroun=
d-size: cover;border: 1px solid #EEEEEE;border-top: 3px solid #DDD;padding=
-top: 9px;padding-bottom: 9px;color: #000000;font-family: Arial=2Csans-ser=
if;font-size: 12px;font-weight: bold;line-height: 150%;text-align: center;=
">
                  <!-- BEGIN MODULE: STANDARD PREHEADER // -->
                  <p style=3D"margin: 1em 0;padding: 0;mso-line-height-rul=
e: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color=
: #000000;font-family: Arial=2Csans-serif;font-size: 12px;font-weight: bol=
d;line-height: 150%;text-align: center;">Sponsored by <span><img src=3D"ht=
tps://gallery.mailchimp.com/f8609630ae206654824f897b6/images/1f63b157-2850=
-49ec-88bb-6c7a4bd1af57.png" width=3D"92" alt=3D"" style=3D"border: 0;heig=
ht: auto;outline: none;text-decoration: none;-ms-interpolation-mode: bicub=
ic;max-width: 550px;vertical-align: middle;margin-bottom: 1px;"></span>
                </p>
                <!-- // END MODULE: STANDARD PREHEADER -->
              </td>
            </tr>
            <!-- // END PREHEADER -->
            <!-- BEGIN SPACER // -->
            <tr>
              <td valign=3D"top" class=3D"templateSpacer" style=3D"mso-lin=
e-height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust=
: 100%;">
                <p style=3D"margin: 0;padding: 0;mso-line-height-rule: exa=
ctly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;font-size:=
 10px;">=C2=A0</p>
              </td>
            </tr>
            <!-- // END SPACER -->
            <!-- BEGIN HEADER // -->
            <tr>
              <td valign=3D"top" class=3D"templateHeader standard" style=
=3D"background:#FFFFFF none no-repeat center/cover;mso-line-height-rule: e=
xactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;padding-r=
ight: 25px;padding-left: 25px;background-color: #FFFFFF;background-image:=
 none;background-repeat: no-repeat;background-position: center;background-=
size: cover;border-top: 3px solid #1FADB6;border-left: 1px solid #EEEEEE;b=
order-right: 1px solid #EEEEEE;padding-top: 18px;padding-bottom: 0;color:=
 #000000;font-family: Arial=2Csans-serif;font-size: 17px;line-height: 150%=
;text-align: left;">
                <!-- BEGIN MODULE: HEADER IMAGE // -->

                <a href=3D"https://statnews.us11.list-manage.com/track/cli=
ck?u=3Df8609630ae206654824f897b6&id=3D5c0b260a8b&e=3Dfecc3a10a2" style=3D=
"mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-siz=
e-adjust: 100%;color: #1FADB6;text-decoration: none;">

                  <img src=3D"https://gallery.mailchimp.com/f8609630ae2066=
54824f897b6/images/10582a1e-bac6-419c-a86a-fc5f40bd63c7.png" width=3D"550"=
 alt=3D"The Readout" style=3D"border: 0;height: auto;outline: none;text-de=
coration: none;-ms-interpolation-mode: bicubic;max-width: 550px;"></a>

                  <!-- // END MODULE: HEADER IMAGE -->
                </td>
              </tr>
              <!-- // END HEADER -->
              <!-- BEGIN INTRO // -->

              <!-- // END INTRO -->
              <!-- BEGIN RULE // -->
              <tr>
                <td valign=3D"top" class=3D"templateRule" style=3D"mso-lin=
e-height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust=
: 100%;border-top: 1px solid #EEEEEE;">
                </td>
              </tr>
              <!-- // END RULE -->
              <tr mc:repeatable=3D"repeat_1" mc:variant=3D"standard" mc:re=
peatindex=3D"0">
                <td valign=3D"top" class=3D"templateBody standard" style=
=3D"background:#FFFFFF none no-repeat center/cover;mso-line-height-rule: e=
xactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;padding-r=
ight: 25px;padding-left: 25px;background-color: #FFFFFF;background-image:=
 none;background-repeat: no-repeat;background-position: center;background-=
size: cover;border-left: 1px solid #EEEEEE;border-right: 1px solid #EEEEEE=
;border-bottom: 1px solid #EEEEEE;padding-top: 0;padding-bottom: 9px;color=
: #000000;font-family: Georgia=2Cserif;font-size: 17px;line-height: 150%;t=
ext-align: left;">
                  <!-- BEGIN MODULE: BODY CONTENT STANDARD // -->
                  <div><h1 style=3D"display: block;margin-top: 24px;margin=
-bottom: 0;padding: 0;color: #000000;font-family: Arial=2Csans-serif;font-=
style: normal;font-weight: bold;line-height: 130%;letter-spacing: normal;t=
ext-align: left;font-size: 22px;">The haves and have-nots of biotech IPOs<=
/h1>

<p style=3D"margin: 1em 0;padding: 0;mso-line-height-rule: exactly;-ms-tex=
t-size-adjust: 100%;-webkit-text-size-adjust: 100%;margin-top: 4px;color:=
 #000000;font-family: Georgia=2Cserif;font-size: 17px;line-height: 150%;te=
xt-align: left;"><br>
As biotech&rsquo;s unprecedentedly open IPO window wraps up its sixth year=
=2C one fact tends to escape attention: Most of these things are bad inves=
tments.<br>
<br>
Analysts at Leerink crunched the numbers on the IPO boom and found that wh=
ile the average return of biotech debutantes is positive=2C the best-perfo=
rming 20 percent of companies account for more than 80 percent of investor=
 benefit. Meanwhile=2C a full 60 percent of biotech IPOs since 2013 have s=
erved up negative returns.<br>
<br>
That means=2C essentially=2C that the story of the biotech boom is one of=
 a few overachieving students goosing the numbers for a C-minus class. And=
 yet it&rsquo;s easy to see why investors keep coming back to the trough:=
 A big bet on one of the 20-percenters would more than make up for a few m=
iscalculations on also-ran drug developers.</p>
</div>
                  <!-- // END MODULE: BODY CONTENT STANDARD -->
                </td>
              </tr><tr mc:repeatable=3D"repeat_1" mc:variant=3D"standard"=
 mc:repeatindex=3D"1">
                <td valign=3D"top" class=3D"templateBody standard" style=
=3D"background:#FFFFFF none no-repeat center/cover;mso-line-height-rule: e=
xactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;padding-r=
ight: 25px;padding-left: 25px;background-color: #FFFFFF;background-image:=
 none;background-repeat: no-repeat;background-position: center;background-=
size: cover;border-left: 1px solid #EEEEEE;border-right: 1px solid #EEEEEE=
;border-bottom: 1px solid #EEEEEE;padding-top: 0;padding-bottom: 9px;color=
: #000000;font-family: Georgia=2Cserif;font-size: 17px;line-height: 150%;t=
ext-align: left;">
                  <!-- BEGIN MODULE: BODY CONTENT STANDARD // -->
                  <div><h1 style=3D"display: block;margin-top: 24px;margin=
-bottom: 0;padding: 0;color: #000000;font-family: Arial=2Csans-serif;font-=
style: normal;font-weight: bold;line-height: 130%;letter-spacing: normal;t=
ext-align: left;font-size: 22px;">Meet the Wunderkinds</h1>

<p style=3D"margin: 1em 0;padding: 0;mso-line-height-rule: exactly;-ms-tex=
t-size-adjust: 100%;-webkit-text-size-adjust: 100%;margin-top: 4px;color:=
 #000000;font-family: Georgia=2Cserif;font-size: 17px;line-height: 150%;te=
xt-align: left;"><br>
Each year at STAT=2C we set out to look past the household names of scienc=
e and spotlight the next generation of researchers at work on what could b=
e the next big thing in medicine.&nbsp;<br>
<br>
Over the past several months=2C we pored through hundreds of nominations f=
rom across North America. We didn&rsquo;t set an age limit; we were on the=
 hunt for the most impressive doctors and researchers on the cusp of launc=
hing their careers but not yet fully independent. Most were postdocs=2C fe=
llows=2C and biopharma employees working with more senior scientists. All=
 are blazing new trails as they attempt to answer some of the biggest ques=
tions in science and medicine.<br>
<br>
And now we present them to you. <a href=3D"https://statnews.us11.list-mana=
ge.com/track/click?u=3Df8609630ae206654824f897b6&id=3D44fedb9d0b&e=3D=
fecc3a10a2" target=3D"_blank" style=3D"mso-line-height-rule: exactly;-ms-text-=
size-adjust: 100%;-webkit-text-size-adjust: 100%;color: #1FADB6;text-decor=
ation: none;">Read more</a>.</p>
</div>
                  <!-- // END MODULE: BODY CONTENT STANDARD -->
                </td>
              </tr><tr mc:repeatable=3D"repeat_1" mc:variant=3D"sponsor" m=
c:repeatindex=3D"2">
                <td valign=3D"top" class=3D"templateBody sponsor" style=3D=
"background:#FFFFFF none no-repeat center/cover;mso-line-height-rule: exac=
tly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;padding-righ=
t: 25px;padding-left: 25px;background-color: #FFFFFF;background-image: non=
e;background-repeat: no-repeat;background-position: center;background-size=
: cover;border-left: 1px solid #EEEEEE;border-right: 1px solid #EEEEEE;bor=
der-bottom: 1px solid #EEEEEE;padding-top: 0;padding-bottom: 9px;color: #0=
00000;font-family: Georgia=2Cserif;font-size: 17px;line-height: 150%;text-=
align: left;">
                  <!-- BEGIN MODULE: BODY CONTENT SPONSOR // -->
                  <div>
                    <p style=3D"margin: 1em 0;padding: 0;mso-line-height-r=
ule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;col=
or: #DF4C51;font-family: Arial=2Csans-serif;font-size: 10px;line-height: 1=
50%;text-align: left;text-transform: uppercase;margin-top: 24px;margin-bot=
tom: 0;letter-spacing: 2px;">Sponsor content by STAT Plus</p>
                    <h1 style=3D"display: block;margin-top: 4px;margin-bot=
tom: 0;padding: 0;color: #000000;font-family: Arial=2Csans-serif;font-styl=
e: normal;font-weight: bold;line-height: 130%;letter-spacing: normal;text-=
align: left;font-size: 22px;">In-depth biopharma=2C business=2C and policy=
 analysis at your fingertips</h1>
                    <p style=3D"margin: 1em 0;padding: 0;mso-line-height-r=
ule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;mar=
gin-top: 4px;color: #000000;font-family: Georgia=2Cserif;font-size: 17px;l=
ine-height: 150%;text-align: left;">Sign up for STAT Plus to receive in-de=
pth analysis of the biotech and pharma industries=2C exclusive one-on-one=
 interviews with industry pioneers=2C and inside intelligence from Capitol=
 Hill. Don=E2=80=99t be the last to know. <a href=3D"https://statnews.us11=
=2Elist-manage.com/track/click?u=3Df8609630ae206654824f897b6&id=3D42ebb08c01=
&e=3Dfecc3a10a2" style=3D"mso-line-height-rule: exactly;-ms-text-size-adj=
ust: 100%;-webkit-text-size-adjust: 100%;color: #DF4C51;text-decoration: n=
one;">Subscribe</a> today to start reading.</p>
                  </div>
                  <!-- // END MODULE: BODY CONTENT SPONSOR -->
                </td>
              </tr><tr mc:repeatable=3D"repeat_1" mc:variant=3D"standard"=
 mc:repeatindex=3D"3">
                <td valign=3D"top" class=3D"templateBody standard" style=
=3D"background:#FFFFFF none no-repeat center/cover;mso-line-height-rule: e=
xactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;padding-r=
ight: 25px;padding-left: 25px;background-color: #FFFFFF;background-image:=
 none;background-repeat: no-repeat;background-position: center;background-=
size: cover;border-left: 1px solid #EEEEEE;border-right: 1px solid #EEEEEE=
;border-bottom: 1px solid #EEEEEE;padding-top: 0;padding-bottom: 9px;color=
: #000000;font-family: Georgia=2Cserif;font-size: 17px;line-height: 150%;t=
ext-align: left;">
                  <!-- BEGIN MODULE: BODY CONTENT STANDARD // -->
                  <div><h1 style=3D"display: block;margin-top: 24px;margin=
-bottom: 0;padding: 0;color: #000000;font-family: Arial=2Csans-serif;font-=
style: normal;font-weight: bold;line-height: 130%;letter-spacing: normal;t=
ext-align: left;font-size: 22px;">Biotech is just swimming in money right=
 now</h1>

<p style=3D"margin: 1em 0;padding: 0;mso-line-height-rule: exactly;-ms-tex=
t-size-adjust: 100%;-webkit-text-size-adjust: 100%;margin-top: 4px;color:=
 #000000;font-family: Georgia=2Cserif;font-size: 17px;line-height: 150%;te=
xt-align: left;"><br>
Last week=2C public market investors poured about $1.3 billion into biotec=
h=2C according to analysts at Piper Jaffray=2C marking the biggest jump in=
 more than a year. Here&rsquo;s why that matters: The flow of money into t=
he sector is strongly correlated with its performance=2C and the past few=
 months of investor interest in biotech reverses two years of negative tre=
nds.<br>
<br>
In 2016=2C roughly $6.5 billion left the sector=2C and the following year=
 was just about flat. This year has already seen more than $4 billion flow=
 into biotech=2C rivaling the heady years of the industry&rsquo;s recent b=
oom.<br>
<br>
There are a few likely explanations. For one=2C the headwinds that sent bi=
otech tanking in 2015 &mdash; concerns about a drug pricing crackdown and=
 uncertainty about the 2016 presidential election &mdash; have largely bee=
n resolved. And for two=2C in the minds of generalist investors=2C the upw=
ard trajectory of biotech and health care at large has come to look more a=
ttractive compared with the once reliable but suddenly volatile tech secto=
r.</p>
</div>
                  <!-- // END MODULE: BODY CONTENT STANDARD -->
                </td>
              </tr><tr mc:repeatable=3D"repeat_1" mc:variant=3D"standard"=
 mc:repeatindex=3D"4">
                <td valign=3D"top" class=3D"templateBody standard" style=
=3D"background:#FFFFFF none no-repeat center/cover;mso-line-height-rule: e=
xactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;padding-r=
ight: 25px;padding-left: 25px;background-color: #FFFFFF;background-image:=
 none;background-repeat: no-repeat;background-position: center;background-=
size: cover;border-left: 1px solid #EEEEEE;border-right: 1px solid #EEEEEE=
;border-bottom: 1px solid #EEEEEE;padding-top: 0;padding-bottom: 9px;color=
: #000000;font-family: Georgia=2Cserif;font-size: 17px;line-height: 150%;t=
ext-align: left;">
                  <!-- BEGIN MODULE: BODY CONTENT STANDARD // -->
                  <div><h1 style=3D"display: block;margin-top: 24px;margin=
-bottom: 0;padding: 0;color: #000000;font-family: Arial=2Csans-serif;font-=
style: normal;font-weight: bold;line-height: 130%;letter-spacing: normal;t=
ext-align: left;font-size: 22px;">A win for prenatal CRISPR</h1>

<p style=3D"margin: 1em 0;padding: 0;mso-line-height-rule: exactly;-ms-tex=
t-size-adjust: 100%;-webkit-text-size-adjust: 100%;margin-top: 4px;color:=
 #000000;font-family: Georgia=2Cserif;font-size: 17px;line-height: 150%;te=
xt-align: left;"><br>
In an early-stage study on mice=2C scientists managed to cure an inherited=
 disease by using CRISPR genome editing on fetuses=2C a promising sign tha=
t the rapidly proliferating technology may offer hope for devastating inbo=
rn disorders.<br>
<br>
As <a href=3D"https://statnews.us11.list-manage.com/track/click?u=3Df86096=
30ae206654824f897b6&id=3Dce4a120050&e=3Dfecc3a10a2" target=3D"_blank" sty=
le=3D"mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-tex=
t-size-adjust: 100%;color: #1FADB6;text-decoration: none;">STAT&rsquo;s Sh=
aron Begley reports</a>=2C researchers at the University of Pennsylvania a=
nd the Children&rsquo;s Hospital of Philadelphia managed to cure a disease=
 called hereditary tyrosinemia type 1 in mice by disabling an errant gene=
=2C an early victory that could pave the way to curing genetic disorders b=
efore birth.<br>
<br>
&ldquo;A lot more animal work needs to be done before we can even think ab=
out applying this clinically=2C&rdquo; said Dr. William Peranteau=2C who c=
o-led the study. &ldquo;But I think fetal genome editing may be where feta=
l surgery&nbsp;once was=2C and that one day we&rsquo;ll use it to treat di=
seases that cause significant morbidity and mortality.&rdquo;<br>
<br>
<a href=3D"https://statnews.us11.list-manage.com/track/click?u=3Df8609630a=
e206654824f897b6&id=3Db02ec4d277&e=3Dfecc3a10a2" target=3D"_blank" style=
=3D"mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-=
size-adjust: 100%;color: #1FADB6;text-decoration: none;">Read more</a>.</p=
>
</div>
                  <!-- // END MODULE: BODY CONTENT STANDARD -->
                </td>
              </tr><tr mc:repeatable=3D"repeat_1" mc:variant=3D"list" mc:r=
epeatindex=3D"5">
                <td valign=3D"top" class=3D"templateBody list" style=3D"ba=
ckground:#FFFFFF none no-repeat center/cover;mso-line-height-rule: exactly=
;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;padding-right:=
 25px;padding-left: 25px;background-color: #FFFFFF;background-image: none;=
background-repeat: no-repeat;background-position: center;background-size:=
 cover;border-left: 1px solid #EEEEEE;border-right: 1px solid #EEEEEE;bord=
er-bottom: 1px solid #EEEEEE;padding-top: 0;padding-bottom: 9px;color: #00=
0000;font-family: Georgia=2Cserif;font-size: 17px;line-height: 150%;text-a=
lign: left;">
                  <!-- BEGIN MODULE: BODY CONTENT LIST // -->
                  <div><h1 style=3D"display: block;margin-top: 24px;margin=
-bottom: 0;padding: 0;color: #000000;font-family: Arial=2Csans-serif;font-=
style: normal;font-weight: bold;line-height: 130%;letter-spacing: normal;t=
ext-align: left;font-size: 22px;">More reads</h1>

<ul style=3D"list-style-type: square;padding-left: 17px;margin-top: 4px;">
=09<li style=3D"mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;-=
webkit-text-size-adjust: 100%;">Questions about funding and purpose loom o=
ver a foundation Congress created to help the FDA. (<a href=3D"https://sta=
tnews.us11.list-manage.com/track/click?u=3Df8609630ae206654824f897b6&id=3D=
f6bdf5a5a5&e=3Dfecc3a10a2" target=3D"_blank" style=3D"mso-line-height-rul=
e: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color=
: #1FADB6;text-decoration: none;">STAT</a>)</li>
=09<li style=3D"mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;-=
webkit-text-size-adjust: 100%;">GlaxoSmithKline helps immunometabolism sta=
rtup Sitryx to $30 million&nbsp;round. (<a href=3D"https://statnews.us11.l=
ist-manage.com/track/click?u=3Df8609630ae206654824f897b6&id=3Dd61b542518&e=
=3Dfecc3a10a2" target=3D"_blank" style=3D"mso-line-height-rule: exactly;-=
ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color: #1FADB6;te=
xt-decoration: none;">FierceBiotech</a>)</li>
=09<li style=3D"mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;-=
webkit-text-size-adjust: 100%;">Three biotech companies are expected to go=
 public this week. (<a href=3D"https://statnews.us11.list-manage.com/track=
/click?u=3Df8609630ae206654824f897b6&id=3D3bc1c1e7b9&e=3Dfecc3a10a2" targ=
et=3D"_blank" style=3D"mso-line-height-rule: exactly;-ms-text-size-adjust:=
 100%;-webkit-text-size-adjust: 100%;color: #1FADB6;text-decoration: none;=
">Business Insider</a>)</li>
</ul>
</div>
                      <!-- // END MODULE: BODY CONTENT LIST -->
                    </td>
                  </tr><tr mc:repeatable=3D"repeat_1" mc:variant=3D"signat=
ure" mc:repeatindex=3D"6">
                    <td valign=3D"top" class=3D"templateBody signature" st=
yle=3D"background:#FFFFFF none no-repeat center/cover;mso-line-height-rule=
: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;paddin=
g-right: 25px;padding-left: 25px;background-color: #FFFFFF;background-imag=
e: none;background-repeat: no-repeat;background-position: center;backgroun=
d-size: cover;border-left: 1px solid #EEEEEE;border-right: 1px solid #EEEE=
EE;border-bottom: 1px solid #EEEEEE;padding-top: 0;padding-bottom: 9px;col=
or: #000000;font-family: Georgia=2Cserif;font-size: 17px;line-height: 150%=
;text-align: left;">
                      <!-- BEGIN MODULE: BODY CONTENT SIGNATURE // -->
                      <div><p style=3D"margin: 1em 0;padding: 0;mso-line-h=
eight-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 1=
00%;color: #000000;font-family: Georgia=2Cserif;font-size: 17px;line-heigh=
t: 150%;text-align: left;"><em>Thanks for reading! Until tomorrow=2C</em><=
/p>
<img alt=3D"Megan" data-file-id=3D"1003769" height=3D"53" src=3D"https://g=
allery.mailchimp.com/f8609630ae206654824f897b6/images/71b06ba8-4013-4ab4-9=
abb-7ec5698e8f6c.png" style=3D"border: 0px;width: 150px;height: 53px;margi=
n: 0px;outline: none;text-decoration: none;-ms-interpolation-mode: bicubic=
;max-width: 550px;vertical-align: text-top;" width=3D"150"></div>
                    <!-- // END MODULE: BODY CONTENT SIGNATURE -->
                  </td>
                </tr>




              <!-- BEGIN FOOTER // -->
              <tr>
                <td valign=3D"top" id=3D"templateFooter" style=3D"backgrou=
nd:#F8F8F8 none no-repeat center/cover;mso-line-height-rule: exactly;-ms-t=
ext-size-adjust: 100%;-webkit-text-size-adjust: 100%;background-color: #F8=
F8F8;background-image: none;background-repeat: no-repeat;background-positi=
on: center;background-size: cover;border-top: 0;border-bottom: 0;padding-t=
op: 0;padding-bottom: 9px;padding-left: 0;padding-right: 0;">
                  <!-- BEGIN MODULE: STANDARD FOOTER // -->
                  <table border=3D"0" cellpadding=3D"0" cellspacing=3D"0"=
 width=3D"100%" style=3D"border-collapse: collapse;mso-table-lspace: 0;mso=
-table-rspace: 0;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%=
;">
                    <tr>
                      <td valign=3D"top" id=3D"dateBar" style=3D"mso-line-=
height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust:=
 100%;text-align: right;font-family: Arial=2Csans-serif;font-size: 10px;co=
lor: #999999;">
                        <p style=3D"margin: 1em 0;padding: 0;mso-line-heig=
ht-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%=
;text-align: right;font-family: Arial=2Csans-serif;font-size: 10px;color:=
 #999999;">Tuesday=2C October 9=2C 2018</p>
                      </td>
                    </tr>
                    <tr>
                      <td valign=3D"top" id=3D"logoBar" style=3D"mso-line-=
height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust:=
 100%;font-family: Arial=2Csans-serif;font-size: 17px;text-align: center;"=
>
                        <p style=3D"margin: 1em 0;padding: 0;mso-line-heig=
ht-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%=
;font-family: Arial=2Csans-serif;font-size: 17px;text-align: center;margin=
-top: 18px;margin-bottom: 9px;"><a href=3D"https://statnews.us11.list-mana=
ge.com/track/click?u=3Df8609630ae206654824f897b6&id=3D2ce20522f2&e=3D=
fecc3a10a2" style=3D"mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;=
-webkit-text-size-adjust: 100%;color: #1FADB6;text-decoration: none;"><img=
 src=3D"https://gallery.mailchimp.com/f8609630ae206654824f897b6/images/d53=
0babb-e16a-4199-b764-b3edc2ad8917.png" width=3D"80" alt=3D"STAT" style=3D"=
border: 0;height: auto;outline: none;text-decoration: none;-ms-interpolati=
on-mode: bicubic;max-width: 550px;"></a>
                      </p>
                    </td>
                  </tr>
                  <tr>
                    <td valign=3D"top" id=3D"socialBar" style=3D"mso-line-=
height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust:=
 100%;background-color: #F8F8F8;border: 0;padding: 0;color: #BBBBBB;font-f=
amily: Arial=2Csans-serif;font-size: 11px;line-height: 150%;text-align: ce=
nter;margin: 0;">
                      <p style=3D"margin: 0;padding: 0;mso-line-height-rul=
e: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color=
: #BBBBBB;font-family: Arial=2Csans-serif;font-size: 11px;line-height: 150=
%;text-align: center;">
                      <a href=3D"https://statnews.us11.list-manage.com/tra=
ck/click?u=3Df8609630ae206654824f897b6&id=3D26ae29d34a&e=3Dfecc3a10a2" st=
yle=3D"mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-te=
xt-size-adjust: 100%;color: #1FADB6;text-decoration: none;"><img src=3D"ht=
tps://gallery.mailchimp.com/f8609630ae206654824f897b6/images/e56a2f39-94b1=
-416d-9b03-cb8cbfff96b7.png" width=3D"30" alt=3D"Facebook" title=3D"Facebo=
ok" style=3D"border: 0;height: auto;outline: none;text-decoration: none;-m=
s-interpolation-mode: bicubic;max-width: 550px;"></a>
                      =C2=A0
                      <a href=3D"https://statnews.us11.list-manage.com/tra=
ck/click?u=3Df8609630ae206654824f897b6&id=3D777921f775&e=3Dfecc3a10a2" st=
yle=3D"mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-te=
xt-size-adjust: 100%;color: #1FADB6;text-decoration: none;"><img src=3D"ht=
tps://gallery.mailchimp.com/f8609630ae206654824f897b6/images/34ace2fa-af9d=
-4cf8-a2c2-e491c02464bd.png" width=3D"30" alt=3D"Twitter" title=3D"Twitter=
" style=3D"border: 0;height: auto;outline: none;text-decoration: none;-ms-=
interpolation-mode: bicubic;max-width: 550px;"></a>
                      =C2=A0
                      <a href=3D"https://statnews.us11.list-manage.com/tra=
ck/click?u=3Df8609630ae206654824f897b6&id=3Dcaf0283eb2&e=3Dfecc3a10a2" st=
yle=3D"mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-te=
xt-size-adjust: 100%;color: #1FADB6;text-decoration: none;"><img src=3D"ht=
tps://gallery.mailchimp.com/f8609630ae206654824f897b6/images/8eab3604-cd8e=
-4bc9-b577-9e98ae898f5b.png" width=3D"30" alt=3D"YouTube" title=3D"YouTube=
" style=3D"border: 0;height: auto;outline: none;text-decoration: none;-ms-=
interpolation-mode: bicubic;max-width: 550px;"></a>
                      =C2=A0
                      <a href=3D"https://statnews.us11.list-manage.com/tra=
ck/click?u=3Df8609630ae206654824f897b6&id=3Dfc34e2b740&e=3Dfecc3a10a2" st=
yle=3D"mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-te=
xt-size-adjust: 100%;color: #1FADB6;text-decoration: none;"><img src=3D"ht=
tps://gallery.mailchimp.com/f8609630ae206654824f897b6/images/c75510f1-ae31=
-4ab6-a80b-9a9f97a5c08e.png" width=3D"30" alt=3D"Instagram" title=3D"Insta=
gram" style=3D"border: 0;height: auto;outline: none;text-decoration: none;=
-ms-interpolation-mode: bicubic;max-width: 550px;"></a>
                    </p>
                  </td>
                </tr>
                <tr>
                  <td valign=3D"top" id=3D"footerContent" style=3D"mso-lin=
e-height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust=
: 100%;padding-top: 5px;padding-bottom: 0;color: #BBBBBB;font-family: Aria=
l=2Csans-serif;font-size: 11px;line-height: 160%;text-align: center;">
                    1 Exchange Pl=2C Suite 201=2C Boston=2C MA 02109
                    <!-- DMD AIM TAG  -->
                    <div style=3D"width:0;overflow:hidden;float:left;displ=
ay:none;margin-bottom:-1px;">
                      <img src=3D"http://www.medtargetsystem.com/_icu.png?=
id=3DX4417792&amp;campaign=3D%7C4972%7C&amp;data=3D=
statnews3@agentidea.com" style=3D"width: 0;overflow: hidden;float: left;display: none;margin-bo=
ttom: -1px;border: 0;height: auto;outline: none;text-decoration: none;-ms-=
interpolation-mode: bicubic;max-width: 550px;" alt=3D"_icu.png?id=3D=
X4417792&amp;campaign=3D%7C4972%7C&amp;data=3Dstatnews3@agentidea.com"><img sr=
c=3D"http://www.medtargetsystem.com/_itu.png" style=3D"width: 0;overflow:=
 hidden;float: left;display: none;margin-bottom: -1px;border: 0;height: au=
to;outline: none;text-decoration: none;-ms-interpolation-mode: bicubic;max=
-width: 550px;" alt=3D"_itu.png">
                    </div>
                    <!-- DMD AIM TAG END -->
                    <br>
                    =C2=A92018=2C All Rights Reserved.
                  </td>
                </tr>
                <tr>
                  <td valign=3D"top" id=3D"utilityBar" style=3D"mso-line-h=
eight-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 1=
00%;background-color: #F8F8F8;border: 0;padding-top: 0;padding-bottom: 20p=
x;color: #BBBBBB;font-family: Arial=2Csans-serif;font-size: 11px;line-heig=
ht: 160%;text-align: center;">
                    <a href=3D"https://statnews.us11.list-manage.com/unsub=
scribe?u=3Df8609630ae206654824f897b6&id=3D8cab1d7961&e=3Dfecc3a10a2&c=3D4303=
964433" class=3D"unsub" style=3D"mso-line-height-rule: exactly;-ms-text-si=
ze-adjust: 100%;-webkit-text-size-adjust: 100%;color: #BBBBBB;text-decorat=
ion: underline;">I no longer wish to receive STAT emails</a>
                    <br><a href=3D"https://statnews.us11.list-manage.com/p=
rofile?u=3Df8609630ae206654824f897b6&id=3D8cab1d7961&e=3Dfecc3a10a2" style=
=3D"mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-=
size-adjust: 100%;color: #1FADB6;text-decoration: underline;">Update=C2=A0=
Email=C2=A0Preferences</a> | <a href=3D"https://statnews.us11.list-manage.=
com/track/click?u=3Df8609630ae206654824f897b6&id=3D2404e4129d&e=3D=
fecc3a10a2" style=3D"mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;-we=
bkit-text-size-adjust: 100%;color: #1FADB6;text-decoration: underline;">Co=
ntact=C2=A0Us</a>
                    <!--
 -->
                    | <a href=3D"https://mailchi.mp/statnews/tk-586945?e=
=3Dfecc3a10a2" style=3D"mso-line-height-rule: exactly;-ms-text-size-adjust:=
 100%;-webkit-text-size-adjust: 100%;color: #1FADB6;text-decoration: under=
line;">View=C2=A0In=C2=A0Browser</a>
                    <!--
 -->
                  </td>
                </tr>
              </table><img src=3D"https://b.bostonglobemedia.com/s/5cP.gif=
?contact_status=3DNewsletter Only" height=3D"1" width=3D"1" alt=3D"5cP.g=
if?contact_status=3DNewsletter Only" style=3D"border: 0;height: auto;out=
line: none;text-decoration: none;-ms-interpolation-mode: bicubic;max-width=
: 550px;">
              <!-- // END MODULE: STANDARD FOOTER -->
            </td>
          </tr>
          <!-- // END FOOTER -->
        </table>
        <!--[if gte mso 9]>
      </td>
    </tr>
  </table>
  <![endif]-->
        <!-- // END TEMPLATE -->
      </td>
    </tr>
  </table>
</center>
<img src=3D"https://statnews.us11.list-manage.com/track/open.php?u=3Df8609=
630ae206654824f897b6&id=3D4303964433&e=3Dfecc3a10a2" height=3D"1" width=
=3D"1"></body>
</html>
--_----------=_MCPart_427971620--

